Cardiovascular risks of COVID-19 antivirals
Several antivirals, including remdesivir, Paxlovid, molnupiravir, and monoclonal antibodies like tixagevimab and cilgavimab, have been repurposed to treat the coronavirus disease 2019 (COVID-19) or received emergency use authorization (EUA). Antimalarial and antiparasitic drugs like ivermectin, hydroxychloroquine, and chloroquine have also been investigated for their potential activity against the severe acute respiratory syndrome coronavirus 2 [...]